Atopic Dermatitis Vaccination Study
We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.
We are seeking volunteers who meet the below criteria to participate in a clinical study to assess if treatment with nemolizumab will impact vaccine immune response in participants with moderate to severe atopic dermatitis when compared to placebo. An optional 4 year long-term extension study in which all patients receive active treatment is available.
- Willing to receive vaccinations (Tdap and meningitis)
- Chronic AD diagnosis for a minimum of 2 years, and shown documented history of inadequate response to topical AD medication(s) within 6 months
- BSA of 10% or greater, 1% is approximately equal to the size of your palm
- Able to attend 7 office visits over 24 weeks
If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.